



Council of the
European Union

Brussels, 18 March 2015
(OR. en)

7326/15
ADD 1

DENLEG 40
AGRI 140
SAN 76

COVER NOTE

From:	European Commission
date of receipt:	17 March 2015
To:	General Secretariat of the Council
No. Cion doc.:	D036607/01 - Annex 1
Subject:	ANNEX to the COMMISSION REGULATION (EU) No .../.. refusing to authorise certain health claims made on foods, other than those referring to the reduction of disease risk and to children's development and health

Delegations will find attached document D036607/01 - Annex 1.

Encl.: D036607/01 - Annex 1



Brussels, **XXX**
SANCO/12039/2014 ANNEX
(POOL/E4/2014/12039/12039-EN
ANNEX.doc) D036607/01
[...] (2014) **XXX** draft

ANNEX 1

ANNEX

to the

COMMISSION REGULATION (EU) No .../..

**refusing to authorise certain health claims made on foods, other than those referring to
the reduction of disease risk and to children's development and health**

ANNEX

Rejected health claims

Application – Relevant provisions of Regulation (EC) No 1924/2006	Nutrient, substance, food or food category	Claim	EFSA opinion reference
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data.	Citrulline-malate	Maintenance of ATP levels through reduction of lactates in excess for an improved recovery from muscle fatigue.	Q-2013-00659
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data.	Olive (<i>Olea europaea L.</i>) leaf water extract	Daily intake of supplemental olive leaf extract polyphenols contributes to the reduction of the blood glucose rise after meals.	Q-2013-00783
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data.	Pacran®	Pacran® helps to inhibit the adhesion of P-fimbriated <i>E. coli</i> to the urinary tract cells.	Q-2013-00889
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data.	A combination of <i>Bifidobacterium longum</i> LA 101, <i>Lactobacillus helveticus</i> LA 102, <i>Lactococcus lactis</i> LA 103 and <i>Streptococcus thermophilus</i> LA 104	Improves intestinal comfort.	Q-2013-00892
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data.	A combination of <i>Bifidobacterium longum</i> LA 101, <i>Lactobacillus helveticus</i> LA 102, <i>Lactococcus lactis</i> LA 103 and <i>Streptococcus thermophilus</i> LA 104	Regulates your (intestinal) transit.	Q-2013-00893

Application – Relevant provisions of Regulation (EC) No 1924/2006	Nutrient, substance, food or food category	Claim	EFSA opinion reference
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data.	A combination of L-threonine, L-valine, L-leucine, L-isoleucine, L-lysine plus chromium picolinate	Contributes to the reduction of the blood glucose rise when consumed together with a carbohydrate rich meal.	Q-2013-00756
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data.	A combination of lutein and zeaxanthin	Lutein together with zeaxanthin helps maintain clarity and contrast of sight in bright light conditions.	Q-2013-00875